Cancer Cell Dormancy in Novel Mouse Models for Reversible Pancreatic Cancer: A Lingering Challenge in the Development of Targeted Therapies

Wan-Chi Lin¹, Nirakar Rajbhandari¹,², and Kay-Uwe Wagner¹,²

Abstract

Significant advances have been made in the identification of key molecular pathways that play pivotal roles in the initiation and progression of pancreatic ductal adenocarcinoma (PDAC). Among the common genetic and epigenetic changes, oncogenic mutations in Kras and upregulation of the c-Myc oncogene are frequent events in PDAC. Using genetically defined in vivo models, several studies have recently demonstrated that expression of mutant Kras and c-Myc is equally important for the initiation and maintenance of pancreatic cancer. The targeted downregulation of a single oncogene resulted in cancer cell death at primary and metastatic sites. These findings are very encouraging and provide a strong rationale for the development of targeted therapies against these oncogenic drivers. Despite what seemed to be a complete response to the ablation of the oncogene, a few dormant cancer cells remained present, and it was demonstrated that they are a cellular reservoir for a swift relapse of pancreatic cancer following oncogene reactivation. This review summarizes the basic principles of cancer dormancy and the applicability of the novel genetic models for reversible metastatic PDAC to elucidate the role of cancer stem cells as well as biologic and molecular mechanisms that mediate the survival of dormant tumor cells.

Cancer Res; 74(8); 1–6. ©2014 AACR.

Introduction

Three of the main goals of cancer therapy as defined by the National Cancer Institute (Bethesda, MD) are the complete eradication of known tumors, preventing cancer recurrence, and blocking a dissemination of malignant cells to distant sites (http://training.seer.cancer.gov/treatment/). The success of radiation, targeted or cytotoxic therapy, and other types of cancer treatment is typically measured by the complete or partial remission of the malignant cells within primary tumors and their metastatic descendants. Even without obvious signs of cancer in patients and what is believed to be a complete response to therapy, minimal residual disease may still be present depending on the sensitivity of the assay that is being used to detect the remaining cancer cells. The residual malignant cells can either remain proliferative or enter a quiescent state where they stop dividing. In the first scenario, which is defined as tumor mass dormancy (1), the remaining small tumor reservoir is a result of equilibrium between cell proliferation and cell death that restricts the physical expansion of the neoplasm. This might be a result of an immune response, lack of blood and nutrient supply or cell intrinsic mechanisms that promote apoptosis during or following cell division. In contrast to this particular type of tumor growth arrest, cancer dormancy is more frequently referred to the condition where residual cancer cells stop dividing and enter a quiescent state. It should be noted that cancer cell dormancy may not only be a manifestation of minimal residual disease following therapy. It may also be a consequence of an earlier dissemination of cancer cells before therapy that remained quiescent at distant sites because they have not yet fully adapted to the new microenvironment (2, 3). In both cases, the residual cancer cells can persist in a dormant stage, and cancer stays asymptomatic for a prolonged period, sometimes for decades. Upon receiving favorable cell intrinsic or extrinsic cues, residual malignant cells can switch to a fast-dividing mode and grow back a clinically overt disease (1). Given the significant implication of dormant cancer cells that serve as a major cellular basis for cancer relapse, understanding their unique biology and elucidating the underlying mechanisms for the maintenance of quiescence will be critical for developing rational therapies against these cells and to reduce the risk of cancer recurrence.

Modeling Cancer Dormancy

The rate of relapse and formation of metastases following chemotherapy is the most obvious indication that a significant subset of patients still has minimal residual disease. Pusztai and colleagues (4) for instance examined the time and rate of
breast cancer recurrence before and after complete clinical response to anthracycline-based combination chemotherapy, and they reported that more than 85% of patients with metastatic cancer had relapsed within 13 years. Detection and characterization of residual tumor cells, which may be in the order of one cancer cell among a million normal cells in the bone marrow (5), are very challenging in a clinical setting, and it is therefore essential to utilize model systems to study the biology of cancer dormancy.

Cell-cycle arrest and expression of ATP-binding cassette (ABC) transporters in a subset of neoplastic cells are two widely accepted mechanisms that promote a selection of drug-resistant and dormant cancer cells during chemotherapy (1, 6, 7). For example, Naumov and colleagues (8) established a metastatic breast cancer model in mice using the transplantation of GFP-labeled mammary carcinoma cell lines, and they clearly demonstrated that treatment with doxorubicin is ineffective in targeting nondividing cancer cells. In addition to xenograft models, recent efforts have been made to model cancer dormancy in vitro based on three-dimensional cocultures of breast cancer cells with cell types predominant in bone marrow (9). Besides elucidating cancer cell intrinsic factors, these novel organotypic model systems have been applied to define the role of the microvasculature as well as the fibrous stroma in tumor cell dormancy and the reawakening of cancer cells from a quiescent state in response to changes in the growth factor milieu (10, 11). Recent advances in modeling multistage carcinogenesis have also verified the importance of adaptive immunity for tumor cell growth arrest, which contributes to cancer dormancy (12).

Novel therapies directed against cancer-specific, molecular targets (i.e., targeted cancer therapies) hold the promise of being more selective for cancer cells, and unlike cytotoxic agents, they should also eradicate quiescent cells. However, studies in patients with chronic myelogenous leukemia (CML) have shown that quiescent leukemia-initiating cells survive even after years of treatment with imatinib, and these cells are responsible for disease relapse upon therapy discontinuation (13). In line with this notion, Hamilton and colleagues (14) have recently demonstrated using mouse models that CML stem cells do not require Bcr/Abl expression for their survival. These observations clearly suggest that cancer cell dormancy is not a phenomenon specific for cytotoxic interventions and will remain a challenging problem following the advent of targeted therapies. Another important implication of these findings is that biologically relevant functions of oncogenes and putative therapeutic targets are restricted to particular cancer cell subtypes. Experimental evidence for this notion was provided in 1996 by Ewald and colleagues (15) using the first doxycycline-inducible model for reversible tumorigenesis. In this model, expression of the cancer-initiating oncogene (i.e., SV40 large T) was only required for certain stages of tumorigenesis. Although subsequent studies using a similar experimental approach have demonstrated that primary and even metastatic cancer cells can remain “addicted” to the expression of genes like c-Myc, mutant Kras, and ErbB2 (16–21), some types of cancers quickly reemerge following reactivation of the oncogene after, what seemed to be, a complete remission upon the initial ablation of the oncogenic driver (for a more comprehensive reviews on this subject, see refs. 22, 23). Collectively, these studies in ligand-regulated tumor models may have provided experimental proof that a few cancer cells can remain dormant following the targeted inhibition of a single oncogene. Not all of these studies, however, clearly discriminate cancer cell dormancy from de novo transformation events that both can result in cancer recurrence.

**Evidence for the presence of pancreatic cancer stem cells that can cause cancer dormancy in genetic models of targeted therapy**

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies, and approximately 80% of the patients have metastatic disease at the time of diagnosis. There is currently no effective therapy to treat PDAC, and chemo- and radiotherapies are merely a part of palliative care (24). As the majority of pancreatic cancer cells carry activating mutations in the Kras gene (25), its encoded GTPase is an attractive protein for targeted therapy. The importance of this protein as a therapeutic target is emphasized by the recent launch of the "RAS initiative" of the National Cancer Institute in the summer of 2013. In line with this notion, two independent research groups have recently shown that expression of mutant Kras is equally required for the initiation as well as maintenance of primary and metastatic PDAC (26–28). Although these studies may herald a very effective strategy to treat pancreatic cancer through inhibition of Kras, the rapid reemergence of primary and metastatic disease following reactivation of this oncogenic driver might be indicative for the existence of dormant cancer cells in this animal model (28). Our team has shown recently that many human PDAC cases as well as Kras-induced pancreatic tumors in mice overexpress c-Myc (29). In contrast to other PDAC models, upregulation of c-Myc in pancreatic progenitors is entirely sufficient to induce metastatic pancreatic cancer after a very short latency. A persistent expression of c-Myc is required for cancer cell survival at primary and metastatic sites regardless of whether neoplastic cells express or lose expression of wild-type p53 in response to Cdkn2a deficiency. Although we observed a macroscopically complete remission of all cancers in response to the downregulation of c-Myc, it was evident that residual cancer cells were still present at primary and metastatic sites. In subsequent transplantation experiments, we confirmed that cancer recurrence following reexpression of c-Myc was caused by residual neoplastic cells and not a de novo transformation of normal cells in the pancreas. To gain better insight into minimal residual disease in this genetic model, we used a Cre/lox-based, cell-fate mapping technique to visualize and isolate GFP-expressing cancer cells from primary and metastatic sites that survived the ablation of the transforming oncogene. The general principle of this labeling method and its application in models for reversible pancreatic cancer to trace dormant neoplastic cells is shown in Fig. 1. Using immunofluorescence staining on histologic sections, we validated that residual tumor cells did not express transgenic or upregulate endogenous c-Myc. In addition, they were neither proliferating nor undergoing cell death, suggesting that these
cells were quiescent, which is a main characteristic for cancer cell dormancy (Fig. 2). The flow-cytometric analysis of GFP-labeled, residual c-Myc-negative tumor cells in comparison with bulk tumor cells expressing exogenous c-Myc revealed that the dormant population was enriched for cells that express cancer stem cell markers (CD24, CD44, CD133, and Sca-1; ref. 29). Following orthotopic retransplantation, we observed a better engraftment and a higher rate of tumor initiation in recipient mice that had received the residual cancer cell population as compared with an equal number of bulk tumor cells. Hence, dormant cancer cells in this model might be enriched for cancer stem cells based on the higher rate of engraftment as well as expression of specific cell surface markers.

As there are currently no cytotoxic, systemic, or targeted therapies to effectively treat metastatic pancreatic cancer, it is evident that treating this disease does not instigate a biologic response or progression that parallels other cancer types such as that of the breast, prostate, or hematopoietic system. Cancer dormancy therefore does not (yet) seem to be a clinically relevant phenomenon for the majority of pancreatic cancers, at least not for unresectable cases. The dismal prognosis combined with a high frequency of oncogenic Kras mutations is compelling reasons why this disease moves to center stage in our persistent efforts aimed at developing targeted therapies against Ras proteins and their downstream effectors, including c-Myc. The biologic response to the targeted ablation of Kras and c-Myc in established pancreatic tumors of genetically engineered mouse models clearly highlights the importance of this signal transducer and transcription factor for the maintenance of metastatic disease. However, these novel genetic models also herald a manifestation of residual disease despite complete oncogene inhibition. This may be a lingering challenge in the development of targeted therapies for PDAC. To accomplish two of the main goals of cancer therapy stated earlier, that is, the complete eradication of tumors and preventing cancer recurrence, it is therefore essential to elucidate intrinsic and extrinsic factors that can contribute to residual disease in pancreatic cancer. The future will tell whether this assumption is premature, but from our collective knowledge about the biology and natural history of other types of cancer such as CML, melanoma, and breast cancer, cancer cell dormancy and recurrence in response to targeted therapy are probable scenarios for PDAC.

Unanswered Questions and Future Directions

The initial molecular analysis of dormant pancreatic cancer cells in the c-Myc–induced tumor model revealed that they do not carry mutations in Kras (29). Therefore, oncogenic Kras does not seem to mediate the survival of cancer cells in the absence of c-Myc expression as previously reported in a mammary tumor model (20). This notion is clearly supported by the fact that cancer cells also remained dormant following the ligand-mediated downregulation of mutant Kras in PDAC (26, 28). Future studies might elucidate whether there are common underlying molecular mechanisms that mediate the survival of dormant tumor cells in the absence of c-Myc or mutant Kras as oncogenic drivers. Although it is likely that cell intrinsic mechanisms play a significant role, it is equally important to experimentally address whether the stroma provides a suitable microenvironment that facilitates cancer cell dormancy and disease recurrence. It was surprising to note that the majority of fibrous stromal cells survived the selective
attrition of carcinoma cells in the c-Myc–induced tumor model (29). The dormant tumor cells, on the other hand, were always in close proximity or entirely embedded in the fibrous stroma in both the primary site and metastatic lesions. It is therefore reasonable to propose that, similar to CML-initiating cells (30), signaling from the microenvironment is an essential component of cancer dormancy. Among various cell types within the stroma, cancer-associated myofibroblasts and stellate cells are known to facilitate the stemness of cancer cells in gastrointestinal (GI) tumors and PDAC (31, 32). These cells produce various growth factors such as Wnt ligands and hepatocyte growth factor that play a crucial role in the maintenance of normal stem cells and cancer-initiating cells in these tissues (33, 34). Therefore, targeting these signaling pathways in the
Dormant Pancreatic Cancer Cells


References


Cancer Research

Cancer Cell Dormancy in Novel Mouse Models for Reversible Pancreatic Cancer: A Lingering Challenge in the Development of Targeted Therapies

Wan-Chi Lin, Nirakar Rajbhandari and Kay-Uwe Wagner

Cancer Res  Published OnlineFirst March 26, 2014.

Updated version  Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-13-3437

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.